| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 09/13/2001 | WO2001066110A2 METHOD FOR THE TREATMENT OF RENAL DYSFUNCTION WITH sPLA2 INHIBITORS |
| 09/13/2001 | WO2001066107A2 Treatment of diseases associated with cytokine production with inhibitors of the tec family of protein tyrosine kinases |
| 09/13/2001 | WO2001066105A1 Method and composition for lightening the skin |
| 09/13/2001 | WO2001066102A2 Oral dosage form for administration of the combination of tegafur, uracil, folinic acid, and oxaliplatin and method of using the same |
| 09/13/2001 | WO2001066101A2 Treatment of psoriasis |
| 09/13/2001 | WO2001066098A2 Therapeutic uses of ppar mediators |
| 09/13/2001 | WO2001066096A2 Compositions for prevention and treatment of dementia |
| 09/13/2001 | WO2001066088A1 New self emulsifying drug delivery system |
| 09/13/2001 | WO2001066085A2 Micellar pharmaceutical compositions for buccal and pulmonary application |
| 09/13/2001 | WO2001066081A2 Pharmaceutical preparations containing saccharose fatty acid esters for controlling the release of active ingredients |
| 09/13/2001 | WO2001029178A3 Epo primary response gene 1, eprg1 |
| 09/13/2001 | WO2001028993A3 Tyrosine kinase inhibitors |
| 09/13/2001 | WO2001026635A3 Bioadhesive nanoparticulate compositions having cationic surface stabilizers |
| 09/13/2001 | WO2001019542A8 Naturally extracted and synthetic hypoglycemic or hypolipidemic compositions |
| 09/13/2001 | WO2001016288A3 Dna encoding the human serine protease c-e |
| 09/13/2001 | WO2001015733A3 Compositions for treating autoimmune disease containing a compounds which regulates icam-lfa-1 interaction and a compounds which regulates cd40-cd40 ligand interaction |
| 09/13/2001 | WO2001015593A3 Compositions for reducing vascular plaque formation and methods of using same |
| 09/13/2001 | WO2001005480A3 Chemokine binding protein of gammaherpesvirus 68 and methods of use therefor |
| 09/13/2001 | WO2001005387A3 Pharmaceutical composition containing trichloroacetic acid, 2-oh benzoic and menthol for topical application, uses and process for the preparation thereof |
| 09/13/2001 | WO2001004282A3 Replication-competent anti-cancer vectors |
| 09/13/2001 | WO2000043790A9 Compositions and methods for the diagnosis and treatment of tumor |
| 09/13/2001 | WO2000040701A9 Non-myeloablative tolerogenic treatment |
| 09/13/2001 | WO2000034780A8 METHODS AND COMPOSITIONS USEFUL FOR TARGETING ACTIVATED VITRONECTIN RECEPTOR αvβ¿3? |
| 09/13/2001 | WO1997042968A3 Administration of histamine for therapeutic purposes |
| 09/13/2001 | WO1997037631A3 Chemotherapeutic veterinary drug containing oxytetracycline, sulfadimidine and neomycin |
| 09/13/2001 | US20010021722 Pharmaceutical compositions comprising monoamine oxidase b inhibitors |
| 09/13/2001 | US20010021720 Synergistic mixture of docletaxel and phosphodiesterase inhibitor |
| 09/13/2001 | US20010021716 Using agonist of nicotinergic acetylcholine receptors |
| 09/13/2001 | US20010021704 Active compounds with cytostatic activity, biological electron acceptors, and pharmaceutically customary additives |
| 09/13/2001 | US20010021516 An isolated nucleic acid molecule comprising a polynucleotide having nucleotide sequence atleast 95% identical to a sequence selected from a nucleotide sequence encoding a TRID polypeptide having specific amino acid sequence |
| 09/13/2001 | US20010021510 Materials and methods for detection and treatment of immune system dysfunctions |
| 09/13/2001 | US20010021507 Renal nuclear matrix protein able to differentiate cancerous renal cell from normal renal cells; useful for diagnosis and producing treatment for cell proliferative disorders of the kidney |
| 09/13/2001 | US20010021397 Solvent extraction from yeast |
| 09/13/2001 | US20010021395 Mixture of nucleic acid and anticancer agent |
| 09/13/2001 | DE10106530A1 Medicament for eliminating toxic agents derived from infected animal feed from the body, comprises uridine diphosphate glucuronic acid, forming water-soluble, inactive conjugates with the toxic agents |
| 09/13/2001 | DE10011081A1 Lacquer formulation for treating and preventing onychomycosis, comprising combination of systemic and topical antimycotic agents in film-forming polymer base |
| 09/13/2001 | CA2413923A1 Treatment of inflammatory dermatoses comprising erythromycin or clarythromycin metronidazole and a gastrointestinal hydrogen pump inhibitor |
| 09/13/2001 | CA2402509A1 Methods and kits for locally administering an active agent to an interstitial space of a host |
| 09/13/2001 | CA2402466A1 Composition consisting of phy906 and chemotherapeutic agents |
| 09/13/2001 | CA2402341A1 Metabotropic glutamate receptor antagonists for treating tolerance and dependency |
| 09/13/2001 | CA2402315A1 Therapeutic uses of ppar mediators |
| 09/13/2001 | CA2402273A1 Methods and compositions for dietary supplements |
| 09/13/2001 | CA2402211A1 Phosphatidyl serine receptors and uses thereof |
| 09/13/2001 | CA2402081A1 A compound that selectively binds to cd123 and use thereof to kill hematologic cancer progenitor cells |
| 09/13/2001 | CA2401541A1 Human protein kinases and protein kinase-like enzymes |
| 09/13/2001 | CA2401454A1 G-protein coupled receptors |
| 09/13/2001 | CA2401398A1 Dna encoding human acid-sensing ion channel bnac4 (asic4) |
| 09/13/2001 | CA2401323A1 Treatment of diseases associated with cytokine production with inhibitors of the tec family of protein tyrosine kinases |
| 09/13/2001 | CA2401055A1 1,5-benzothiazepines and their use as hypolipidaemics |
| 09/13/2001 | CA2400628A1 Use of tgf-beta antagonists to treat or to prevent loss of renal function |
| 09/13/2001 | CA2400571A1 Treatment of psoriasis |
| 09/13/2001 | CA2400504A1 Composition for the treatment of heart failure |
| 09/13/2001 | CA2400410A1 Antimicrobial compounds and formulations |
| 09/13/2001 | CA2399111A1 New aza-indolyl derivatives |
| 09/13/2001 | CA2399055A1 Synergistic activation of regulatory elements by rel proteins and a steroid receptor |
| 09/12/2001 | EP1132403A1 Tgf g beta1 inhibitor peptides |
| 09/12/2001 | EP1132394A1 Stable analogs of bioactive peptides containing disulfide linkages |
| 09/12/2001 | EP1132389A1 New aza-indolyl derivatives for the treatment of obesity |
| 09/12/2001 | EP1132088A2 Method for inhibiting bone resorption |
| 09/12/2001 | EP1132086A2 Use of prostaglandin (PGE2) receptor 4 (EP4) selective agonists for the treatment of acute and chronic renal failure |
| 09/12/2001 | EP1131634A2 Determining the mechanism of beta-amyloid peptide generation |
| 09/12/2001 | EP1131633A2 Hiv-specific t-cell induction |
| 09/12/2001 | EP1131464A1 Method for screening for substances which are activators, inhibitors or binders of pkb by the use of a substrate peptide and the use of the substrate peptide |
| 09/12/2001 | EP1131463A1 Use of activated trap for screening for specific inhibitor of trap and method for aiding in the identification of a compound for use in the treatment of diseases or degenerative conditions resulting in increased bone resorption |
| 09/12/2001 | EP1131458A1 Viral vectors with late transgene expression |
| 09/12/2001 | EP1131449A1 Method for identifying inhibitors of ipc synthase |
| 09/12/2001 | EP1131445A1 Human phospholipases |
| 09/12/2001 | EP1131443A2 Human hydrolase proteins |
| 09/12/2001 | EP1131440A2 Process for oxidising terpenes |
| 09/12/2001 | EP1131433A1 Members of the capsaicin/vanilloid receptor family of proteins and uses thereof |
| 09/12/2001 | EP1131429A1 Calcium binding protein |
| 09/12/2001 | EP1131350A1 Egf-like nucleic acids and polypeptides and uses thereof |
| 09/12/2001 | EP1131349A2 Potassium channel interactors and uses therefor |
| 09/12/2001 | EP1131344A2 Retro-inversion peptides that target git transport receptors and related methods |
| 09/12/2001 | EP1131334A1 Use of core 2 glcnac transferase inhibitors in treating inflammation |
| 09/12/2001 | EP1131333A1 ISOLATED NUCLEIC ACID MOLECULES WHICH ENCODE T CELL INDUCIBLE FACTORS (TIFs), THE PROTEINS ENCODED, AND USES THEREOF |
| 09/12/2001 | EP1131135A1 Composition containing an analgesic and a xanthine cor a xanthine derivative |
| 09/12/2001 | EP1131106A1 Compositions and methods for producing vascular occlusion |
| 09/12/2001 | EP1131105A1 Complexes of hyaluronic acid/carnitines and pharmaceutical and cosmetic compositions |
| 09/12/2001 | EP1131102A2 Combination of a gaba-a alpha 5 inverse agonist and cox-2 inhibitor, nsaid, estrogen or vitamin e |
| 09/12/2001 | EP1131097A1 Anti-icam-r antibody-induced apoptosis |
| 09/12/2001 | EP1131088A2 NF-$g(k)B ACTIVATION INHIBITORS, AND THEIR PHARMACEUTICAL USES |
| 09/12/2001 | EP1131086A2 Nf-at mediates cardiac hypertrophy, methods and reagents related thereto |
| 09/12/2001 | EP1131084A1 Inhibition of differentiation of cytotoxic t-cells by p-selectin ligand (psgl) antagonists |
| 09/12/2001 | EP1131083A1 Treatment of tumors by administration of growth hormone releasing compounds and their antagonists |
| 09/12/2001 | EP1131076A1 Method for treating a patient with neoplasia by treatment with an anthracycline antibiotic |
| 09/12/2001 | EP1131070A1 Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent |
| 09/12/2001 | EP1131069A1 Method for treating a patient with neoplasia by treatment with a platinum coordination complex |
| 09/12/2001 | EP1131067A1 Composition and use of rar antagonists for promoting chondrogenesis |
| 09/12/2001 | EP1131062A1 Injectable propofol formulations |
| 09/12/2001 | EP1131060A2 Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an hmg coa reductase inhibitor |
| 09/12/2001 | EP1131052A1 Vaginally administrable progesterone-containing tablets and method for preparing same |
| 09/12/2001 | EP1131051A1 Pressurised metered dose inhalers (mdi) |
| 09/12/2001 | EP1131039A2 Use of a substance binding with the peripheral benzodiazepin receptor for treating skin stress |
| 09/12/2001 | EP1131037A1 Process for the manufacture of liquid filled capsules |
| 09/12/2001 | EP1130969A1 Murf2 polypeptides and polynucleotides |
| 09/12/2001 | EP1130964A1 Therapeutic anti-fungal nail preparation |
| 09/12/2001 | EP1093580A4 Diagnosis of predisposition to epilepsy and monitoring of antiepileptic treatment |
| 09/12/2001 | EP1032424B1 Combination of an aldose reductase inhibitor and a glycogen phosphorylase inhibitor |
| 09/12/2001 | EP0991424B1 Pharmaceutical compositions comprising an aldose reductase inhibitor and an ace inhibitor |